- Home
- SCNI
as 06-26-2025 4:00pm EST
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | JERUSALEM |
| Market Cap: | 3.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $1.90 - $8.92 | Next Earning Date: | 08-14-2025 |
| Revenue: | $658,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Scinai Immunotherapeutics Ltd. News
SCNI Breaking Stock News: Dive into SCNI Ticker-Specific Updates for Smart Investing
PR Newswire
3 days ago
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
PR Newswire
17 days ago
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025
PR Newswire
24 days ago
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
PR Newswire
a month ago
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
PR Newswire
2 months ago
Scinai Announces Annual Financial Results for 2024
PR Newswire
2 months ago
Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases
PR Newswire
3 months ago
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
PR Newswire
3 months ago
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
Compare SCNI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SCNI Scinai Immunotherapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.